 Connection
Thomas Delong to Islet Amyloid Polypeptide
This is a "connection" page, showing publications Thomas Delong has written about Islet Amyloid Polypeptide.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.765 |
|
|
|
-
Delong T, Baker RL, Reisdorph N, Reisdorph R, Powell RL, Armstrong M, Barbour G, Bradley B, Haskins K. Islet amyloid polypeptide is a target antigen for diabetogenic CD4+ T cells. Diabetes. 2011 Sep; 60(9):2325-30.
Score: 0.372
-
Baker RL, Jamison BL, Wiles TA, Lindsay RS, Barbour G, Bradley B, Delong T, Friedman RS, Nakayama M, Haskins K. CD4 T Cells Reactive to Hybrid Insulin Peptides Are Indicators of Disease Activity in the NOD Mouse. Diabetes. 2018 09; 67(9):1836-1846.
Score: 0.151
-
Wiles TA, Delong T, Baker RL, Bradley B, Barbour G, Powell RL, Reisdorph N, Haskins K. An insulin-IAPP hybrid peptide is an endogenous antigen for CD4 T cells in the non-obese diabetic mouse. J Autoimmun. 2017 03; 78:11-18.
Score: 0.134
-
Baker RL, Delong T, Barbour G, Bradley B, Nakayama M, Haskins K. Cutting edge: CD4 T cells reactive to an islet amyloid polypeptide peptide accumulate in the pancreas and contribute to disease pathogenesis in nonobese diabetic mice. J Immunol. 2013 Oct 15; 191(8):3990-4.
Score: 0.108
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|